Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas.
Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayashi T. Motomura K, et al. Among authors: ito i. Cancer Sci. 2012 Oct;103(10):1871-9. doi: 10.1111/j.1349-7006.2012.02377.x. Epub 2012 Aug 7. Cancer Sci. 2012. PMID: 22747609 Free PMC article.
Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A. Aoki K, et al. Among authors: ito i. Neuro Oncol. 2018 Jan 10;20(1):66-77. doi: 10.1093/neuonc/nox132. Neuro Oncol. 2018. PMID: 29016839 Free PMC article.
Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
Nishikawa T, Watanabe R, Kitano Y, Yamamichi A, Motomura K, Ohka F, Aoki K, Hirano M, Kato A, Yamaguchi J, Maeda S, Kibe Y, Saito R, Wakabayashi T, Kato Y, Sato S, Ogino T, Natsume A, Ito I. Nishikawa T, et al. Among authors: ito i. Brain Tumor Pathol. 2022 Jan;39(1):14-24. doi: 10.1007/s10014-021-00418-x. Epub 2021 Nov 26. Brain Tumor Pathol. 2022. PMID: 34826036
CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A. Shiina S, et al. Among authors: ito i. Cancer Immunol Res. 2016 Mar;4(3):259-68. doi: 10.1158/2326-6066.CIR-15-0060. Epub 2016 Jan 28. Cancer Immunol Res. 2016. PMID: 26822025
Mutational landscape and clonal architecture in grade II and III gliomas.
Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S. Suzuki H, et al. Among authors: ito i. Nat Genet. 2015 May;47(5):458-68. doi: 10.1038/ng.3273. Epub 2015 Apr 13. Nat Genet. 2015. PMID: 25848751
Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial.
Mitsuya K, Akiyama Y, Iizuka A, Miyata H, Deguchi S, Hayashi N, Maeda C, Kondou R, Kanematsu A, Watanabe K, Ashizawa T, Abe Y, Ito I, Oishi T, Sugino T, Nakasu Y, Yamaguchi K. Mitsuya K, et al. Among authors: ito i. Anticancer Res. 2020 Nov;40(11):6473-6484. doi: 10.21873/anticanres.14669. Anticancer Res. 2020. PMID: 33109586 Clinical Trial.
837 results